{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T13:02:20Z","timestamp":1782997340308,"version":"3.54.5"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016346","name":"The Second Hospital of Tianjin Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016346","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.thromres.2024.04.011","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T02:59:14Z","timestamp":1713236354000},"page":"41-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["WY-14643, a novel antiplatelet and antithrombotic agent targeting the GPIb\u03b1 receptor"],"prefix":"10.1016","volume":"238","author":[{"given":"Chen","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshuang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuangzhuang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peilin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongren","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10258","key":"10.1016\/j.thromres.2024.04.011_bb0005","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"396","author":"Diseases","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.thromres.2024.04.011_bb0010","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1161\/CIRCRESAHA.121.318535","article-title":"Epidemiology of peripheral artery disease and Polyvascular disease","volume":"128","author":"Aday","year":"2021","journal-title":"Circ. Res."},{"issue":"9","key":"10.1016\/j.thromres.2024.04.011_bb0015","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1161\/CIR.0000000000001005","article-title":"Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association","volume":"144","author":"Criqui","year":"2021","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.thromres.2024.04.011_bb0020","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCRESAHA.114.301597","article-title":"Platelet lipidomics: modern day perspective on lipid discovery and characterization in platelets","volume":"114","author":"O\u2019Donnell","year":"2014","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.thromres.2024.04.011_bb0025","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial cell dysfunction and the pathobiology of atherosclerosis","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ. Res."},{"issue":"12","key":"10.1016\/j.thromres.2024.04.011_bb0030","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1161\/CIRCRESAHA.121.318258","article-title":"Contemporary medical Management of Peripheral Artery Disease","volume":"128","author":"Bonaca","year":"2021","journal-title":"Circ. Res."},{"issue":"10332","key":"10.1016\/j.thromres.2024.04.011_bb0035","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(21)02391-6","article-title":"Acute coronary syndromes","volume":"399","author":"Bergmark","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.thromres.2024.04.011_bb0040","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1161\/STROKEAHA.120.031707","article-title":"Stroke prevention in older adults: recent advances","volume":"51","author":"Spence","year":"2020","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.thromres.2024.04.011_bb0045","doi-asserted-by":"crossref","first-page":"145","DOI":"10.5853\/jos.2018.00773","article-title":"Recent advances in primary and secondary prevention of atherosclerotic stroke","volume":"20","author":"Tsivgoulis","year":"2018","journal-title":"J Stroke"},{"key":"10.1016\/j.thromres.2024.04.011_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154338","article-title":"The role of peroxisome proliferator-activated receptors (PPAR) in immune responses","volume":"114","author":"Christofides","year":"2021","journal-title":"Metabolism"},{"issue":"22","key":"10.1016\/j.thromres.2024.04.011_bb0055","doi-asserted-by":"crossref","first-page":"10539","DOI":"10.1093\/nar\/gkw742","article-title":"Chromatin recruitment of activated AMPK drives fasting response genes co-controlled by GR and PPARalpha","volume":"44","author":"Ratman","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.011_bb0060","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3324\/haematol.2021.279770","article-title":"Critical role of peroxisome proliferator-activated receptor alpha in promoting platelet hyperreactivity and thrombosis under hyperlipidemia","volume":"107","author":"Li","year":"2022","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.thromres.2024.04.011_bb0065","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood-2004-03-0926","article-title":"Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes","volume":"104","author":"Akbiyik","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2024.04.011_bb0070","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00063030-200620040-00004","article-title":"Platelets as a novel target for PPARgamma ligands: implications for inflammation, diabetes, and cardiovascular disease","volume":"20","author":"Ray","year":"2006","journal-title":"BioDrugs"},{"issue":"5","key":"10.1016\/j.thromres.2024.04.011_bb0075","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/ATVBAHA.108.183160","article-title":"Antiplatelet actions of statins and fibrates are mediated by PPARs","volume":"29","author":"Ali","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.011_bb0080","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1538-7836.2004.00692.x","article-title":"Role of protease-activated and ADP receptor subtypes in thrombin generation on human platelets","volume":"2","author":"Dorsam","year":"2004","journal-title":"J. Thromb. Haemost."},{"issue":"9","key":"10.1016\/j.thromres.2024.04.011_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24098298","article-title":"Species differences in platelet protease-activated receptors","volume":"24","author":"Renna","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.011_bb0090","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1073\/pnas.050582097","article-title":"Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome","volume":"97","author":"Ware","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.thromres.2024.04.011_bb0095","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1182\/blood.V69.5.1524.1524","article-title":"Glycoprotein Ib and glyco- protein IX are fully complexed in the intact platelet membrane","volume":"69","author":"Du","year":"1987","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.thromres.2024.04.011_bb0100","doi-asserted-by":"crossref","first-page":"13336","DOI":"10.1073\/pnas.96.23.13336","article-title":"Increased thrombin responsiveness in platelets from mice lacking glycoprotein V","volume":"96","author":"Ramakrishnan","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.thromres.2024.04.011_bb0105","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/MOH.0b013e3280dce51a","article-title":"Signaling and regulation of the platelet glycoprotein Ib-IX-V complex","volume":"14","author":"Du","year":"2007","journal-title":"Curr. Opin. Hematol."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.011_bb0110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1124\/mol.116.106666","article-title":"Contributions of protease-activated receptors PAR1 and PAR4 to thrombin-induced GPIIbIIIa activation in human platelets","volume":"91","author":"Duvernay","year":"2017","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.thromres.2024.04.011_bb0115","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1172\/JCI109000","article-title":"Reduced thrombin binding and aggregation in Bernard-Soulier platelets","volume":"61","author":"Jamieson","year":"1978","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.011_bb0120","first-page":"894","article-title":"Unravelling the mechanism and significance of thrombin binding to platelet glycoprotein Ib","volume":"104","author":"Ruggeri","year":"2010","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.011_bb0125","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2015-04-638387","article-title":"Signaling-mediated cooperativity between glycoprotein Ib-IX and protease-activated receptors in thrombin-induced platelet activation","volume":"127","author":"Estevez","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2024.04.011_bb0130","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood-2002-12-3882","article-title":"Platelet-collagen interaction: is GPVI the central receptor?","volume":"102","author":"Nieswandt","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.thromres.2024.04.011_bb0135","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/01.ATV.0000142376.30582.ed","article-title":"ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels","volume":"24","author":"Wihlborg","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"10","key":"10.1016\/j.thromres.2024.04.011_bb0140","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1007\/BF01923636","article-title":"A potent antihypercholesterolemic agent: (4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio) acetic acid (Wy-14643)","volume":"30","author":"Santilli","year":"1974","journal-title":"Experientia"},{"issue":"24","key":"10.1016\/j.thromres.2024.04.011_bb0145","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1161\/01.CIR.99.24.3125","article-title":"PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells","volume":"99","author":"Marx","year":"1999","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.thromres.2024.04.011_bb0150","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/CIRCULATIONAHA.105.536318","article-title":"Downregulation of peroxisome proliferator-activated receptor-alpha gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity","volume":"112","author":"Dewald","year":"2005","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.thromres.2024.04.011_bb0155","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1182\/bloodadvances.2020002493","article-title":"Omega-6 DPA and its 12-lipoxygenase-oxidized lipids regulate platelet reactivity in a nongenomic PPARalpha-dependent manner","volume":"4","author":"Yeung","year":"2020","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.thromres.2024.04.011_bb0160","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/13543776.2017.1272578","article-title":"Therapeutic applications of the versatile fatty acid mimetic WY14643","volume":"27","author":"Pollinger","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.thromres.2024.04.011_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114315","article-title":"GSK669, a NOD2 receptor antagonist, inhibits thrombosis and oxidative stress via targeting platelet GPVI","volume":"183","author":"Pan","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.thromres.2024.04.011_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114822","article-title":"NOD2-mediated P2Y(12) upregulation increases platelet activation and thrombosis in sepsis","volume":"194","author":"Zhong","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"37","key":"10.1016\/j.thromres.2024.04.011_bb0175","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1093\/eurheartj\/ehac034","article-title":"Galectin 3 enhances platelet aggregation and thrombosis via Dectin-1 activation: a translational study","volume":"43","author":"Chen","year":"2022","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.thromres.2024.04.011_bb0180","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/CIRCULATIONAHA.116.026995","article-title":"Platelets express activated P2Y(12) receptor in patients with diabetes mellitus","volume":"136","author":"Hu","year":"2017","journal-title":"Circulation"},{"issue":"6141","key":"10.1016\/j.thromres.2024.04.011_bb0185","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1233606","article-title":"Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay","volume":"341","author":"Martinez Molina","year":"2013","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.thromres.2024.04.011_bb0190","doi-asserted-by":"crossref","first-page":"975","DOI":"10.4155\/fmc.15.50","article-title":"CETSA: a target engagement assay with potential to transform drug discovery","volume":"7","author":"Jensen","year":"2015","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.thromres.2024.04.011_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114864","article-title":"Dictamnine, a novel c-met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K\/AKT\/mTOR and MAPK signaling pathways","volume":"195","author":"Yu","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.011_bb0200","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1160\/TH11-06-0400","article-title":"BF061, a novel antiplatelet and antithrombotic agent targeting P2Y receptor and phosphodiesterase","volume":"106","author":"Hu","year":"2011","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.04.011_bb0205","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3539649","article-title":"Protective effect of peroxisome proliferator-activated receptor alpha activation against cardiac ischemia-reperfusion injury is related to upregulation of uncoupling Protein-3","volume":"2016","author":"Song","year":"2016","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"9","key":"10.1016\/j.thromres.2024.04.011_bb0210","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1161\/CIRCRESAHA.122.321787","article-title":"IL-37 attenuates platelet activation and thrombosis through IL-1R8 pathway","volume":"132","author":"Chen","year":"2023","journal-title":"Circ. Res."},{"issue":"10","key":"10.1016\/j.thromres.2024.04.011_bb0215","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/jth.12362","article-title":"Tumor vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid inhibits platelet activation and thrombosis via inhibition of thromboxane A2 signaling and phosphodiesterase","volume":"11","author":"Zhang","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.011_bb0220","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1160\/TH11-06-0400","article-title":"BF061, a novel antiplatelet and antithrombotic agent targeting P2Y(1)(2) receptor and phosphodiesterase","volume":"106","author":"Hu","year":"2011","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.011_bb0225","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.120.046290","article-title":"PCSK9 (Proprotein convertase Subtilisin\/Kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36","volume":"143","author":"Qi","year":"2021","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.thromres.2024.04.011_bb0230","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1055\/s-0029-1220324","article-title":"Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function","volume":"35","author":"Cattaneo","year":"2009","journal-title":"Semin. Thromb. Hemost."},{"issue":"3","key":"10.1016\/j.thromres.2024.04.011_bb0235","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-0036-1571307","article-title":"Platelet function tests in bleeding disorders","volume":"42","author":"Lassila","year":"2016","journal-title":"Semin. Thromb. Hemost."},{"issue":"7","key":"10.1016\/j.thromres.2024.04.011_bb0240","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1074\/jbc.M008160200","article-title":"Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of par-1 on intact platelets","volume":"276","author":"De Candia","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.011_bb0245","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3324\/haematol.2008.003178","article-title":"Platelet receptors and signaling in the dynamics of thrombus formation","volume":"94","author":"Rivera","year":"2009","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.thromres.2024.04.011_bb0250","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13045-019-0709-6","article-title":"Platelet integrin alphaIIbbeta3: signal transduction, regulation, and its therapeutic targeting","volume":"12","author":"Huang","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"14","key":"10.1016\/j.thromres.2024.04.011_bb0255","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2017-03-773614","article-title":"Integrin alpha(IIb)beta(3) outside-in signaling","volume":"130","author":"Durrant","year":"2017","journal-title":"Blood"},{"issue":"6294","key":"10.1016\/j.thromres.2024.04.011_bb0260","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/347645a0","article-title":"Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators","volume":"347","author":"Issemann","year":"1990","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.thromres.2024.04.011_bb0265","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","article-title":"The PPARs: from orphan receptors to drug discovery","volume":"43","author":"Willson","year":"2000","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.011_bb0270","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood.2020008028","article-title":"Structure of the platelet glycoprotein Ib receptor in complex with a novel antithrombotic agent","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"5584","key":"10.1016\/j.thromres.2024.04.011_bb0275","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1126\/science.107355","article-title":"Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain","volume":"297","author":"Huizinga","year":"2002","journal-title":"Science"},{"issue":"5630","key":"10.1016\/j.thromres.2024.04.011_bb0280","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1126\/science.1084183","article-title":"Modulation of alpha-thrombin function by distinct interactions with platelet glycoprotein Ibalpha","volume":"301","author":"Celikel","year":"2003","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.thromres.2024.04.011_bb0285","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1055\/s-0042-1758654","article-title":"Drug-drug interaction between antiplatelet therapy and lipid-lowering agents (statins and PCSK9 inhibitors)","volume":"123","author":"Schror","year":"2023","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2024.04.011_bb0290","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/STROKEAHA.122.040500","article-title":"Early antiplatelet resumption and the risks of major bleeding after intracerebral hemorrhage","volume":"54","author":"Liu","year":"2023","journal-title":"Stroke"},{"key":"10.1016\/j.thromres.2024.04.011_bb0295","doi-asserted-by":"crossref","DOI":"10.1007\/s10557-023-07459-8","article-title":"Rhabdomyolysis with co-administration of statins and antiplatelet therapies-analysis of the WHO pharmacovigilance database","author":"Roule","year":"2023","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"10","key":"10.1016\/j.thromres.2024.04.011_bb0300","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1073\/pnas.89.10.4653","article-title":"Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor","volume":"89","author":"Gottlicher","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.thromres.2024.04.011_bb0305","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/01.RES.0000060700.55247.7C","article-title":"Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta\/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism","volume":"92","author":"Gilde","year":"2003","journal-title":"Circ. Res."},{"key":"10.1016\/j.thromres.2024.04.011_bb0310","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.biochi.2016.12.019","article-title":"The role and regulation of the peroxisome proliferator activated receptor alpha in human liver","volume":"136","author":"Kersten","year":"2017","journal-title":"Biochimie"},{"issue":"3","key":"10.1016\/j.thromres.2024.04.011_bb0315","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.vph.2014.05.008","article-title":"Mechanism of antiplatelet action of hypolipidemic, antidiabetic and antihypertensive drugs by PPAR activation: PPAR agonists: new antiplatelet agents","volume":"62","author":"Fuentes","year":"2014","journal-title":"Vasc. Pharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2024.04.011_bb0320","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1538-7836.2009.03370.x","article-title":"Integrins in platelet activation","volume":"7","author":"Nieswandt","year":"2009","journal-title":"J. Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2024.04.011_bb0325","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.thromres.2024.04.011_bb0330","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/blood-2017-10-784074","article-title":"The search for new antithrombotic mechanisms and therapies that may spare hemostasis","volume":"131","author":"Plow","year":"2018","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.thromres.2024.04.011_bb0335","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.2174\/138161207781662867","article-title":"Inhibition of platelet glycoprotein Ib and its antithrombotic potential","volume":"13","author":"Vanhoorelbeke","year":"2007","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.011_bb0340","article-title":"In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIbalpha","volume":"11","author":"Li","year":"2021","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.thromres.2024.04.011_bb0345","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1160\/TH13-06-0490","article-title":"Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis","volume":"111","author":"Lei","year":"2014","journal-title":"Thromb. Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824001245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824001245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T08:39:53Z","timestamp":1716021593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824001245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":69,"alternative-id":["S0049384824001245"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.04.011","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WY-14643, a novel antiplatelet and antithrombotic agent targeting the GPIb\u03b1 receptor","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}